Albert Labs International Corp. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was CAD 0.158388 million.
The company's proprietary manufacturing methodology, developed and validated in-house at Albert Labs' Vancouver facility, facilitates the production and scaling of highly potent yields of its KRN Active Pharmaceutical Ingredient.
/CNW/ - Albert Labs International Corp. (Albert Labs (CSE: ABRT) (FSE: VB50), the "Company"), a pharmaceutical drug development company focussed on gaining.
/CNW/ - Albert Labs International Corp. (CSE: ABRT) (FSE: VB50) (the "Company"), a research and drug development company using advanced culture technology to.